Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This phase Ib combination study is being conducted to assess the safety and tolerability of
radium Ra 223 dichloride in combination with paclitaxel in cancer subjects with bone lesions
with special focus on Grade 3/4 incidence of neutro- and/or thrombocytopenia and exploration
of the mode of interaction (i.e. additive or synergistic interaction) between the selected
chemotherapy and radium Ra 223 dichloride with regard to myelosuppression.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Albumin-Bound Paclitaxel Paclitaxel Radium Ra 223 dichloride Succinylcholine